CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies

1.    Executive Summary

2.    Global Chimeric Antigen Receptor (CAR)-T cell Therapy Market

3.    Market Share – CAR-T Cell Therapy

3.1    By Geographical Region
3.2    By Targeted Antigens

4.    Targeted Antigen Market

4.1    CD19

4.1.1    Introduction
4.1.2    Market Size and Forecast

4.2    CD20

4.2.1    Introduction
4.2.2    Market Size and Forecast

4.3    GD2

4.3.1    Introduction
4.3.2    Market Size and Forecast

4.4    CD22

4.4.1    Introduction
4.4.2    Market Size and Forecast

4.5    CD30

4.5.1    Introduction
4.5.2    Market Size and Forecast

4.6    CD33

4.6.1    Introduction
4.6.2    Market Size and Forecast

4.7    HER2

4.7.1    Introduction
4.7.2    Market Size and Forecast

4.8    Mesothelin (MESO)

4.8.1    Introduction
4.8.2    Market Size and Forecast

4.9    EGFRvIII

4.9.1    Introduction
4.9.2    Market Size and Forecast

4.10    Others

4.10.1    Market Size and Forecast

5.    Geographical CAR-T Cell Therapy Market (2016 -2026)

5.1    North America
5.2    Europe
5.3    Asia Pacific
5.4    Latin America
5.5    Middle East
5.6    Africa

6.    Global - CAR-T Cell Clinical Trials/Study

6.1    CD19
6.2    CD20
6.3    CD22
6.4    CD30
6.5    CD33
6.6    EGFRvIII
6.7    GD2
6.8    HER1
6.9    HER2
6.10    MESO

7.    China CAR-T Cells Clinical Trials Details

7.1    By Cities CAR-T Cells Clinical Trials
7.2    CD19 Directed CAR-T Cells Clinical Trials
7.3    Non-CD19 Directed CAR-T Cells Clinical Trials
7.4    Solid Tumors CAR-T Cells Clinical Trials

8.    CAR-T Cell Therapy SWOT Analysis

8.1    Strength
8.2    Weakness
8.3    Opportunities
8.4    Threats

9.    Regulation in CAR-T Cell Therapy

9.1    United States
9.2    European Union
9.3    China

10.    IPO/Investment/Funding/Partnership in CAR-T Cell Therapy Market

10.1    Venture Capital Investment
10.2    Initial Public Offerings of CAR-T Companies
10.3    CAR-T Companies Strategic Partnerships/Deals
10.4    Key CAR-T Technology Deals

11.    Growth Drivers

11.1    FDA Approvals of CAR-T Therapy
11.2    Dramatically Increasing Number of CAR-T Cell Trials Globally

12.    Challenges

12.1    Regulatory Challenges
12.2    Very Expensive CAR-T Therapy Treatment

13.    Novartis

13.1    Company Overview
13.2    Initiatives

13.2.1    Point 1
13.2.2    Point 2 Kymriah® (tisagenlecleucel), First-in-class CAR-T Therapy from Novartis Received Second FDA Approval
13.2.3    Point 2

13.3    Financial Insight

14.    Gilead Sciences (Kite Pharma)

14.1    Company Overview
14.2    Company Initiatives

14.2.1    Point 1
14.2.2    Point 2

14.3    Company Financial Insight

15.    Celgene Corporation (Juno Therapeutics)

15.1    Company Overview
15.2    Company Initiatives

15.2.1    Point 1
15.2.2    Point 2

15.3    Company Financial Insight

16.    Celyad

16.1    Company Overview
16.2    Company Initiatives

16.2.1    Point 1
16.2.2    Point 2
16.2.3    Point 3

16.3    Financial Insight

List of Figures:

Figure 2‑1:    Global – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 2‑2:    Global – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 3‑1:    Global – CAR-T Cell Therapy Regional Market Share (Percent), 2017 – 2019
Figure 3‑2:    Global – Forecast for CAR-T Cell Therapy Regional Market Share (Percent), 2020 – 2028
Figure 4‑1:    Global – CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 4‑2:    Global – CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4‑3:    Global – Forecast for CD20 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4‑4:    Global – Forecast for GD2 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4‑5:    Global – Forecast for CD22 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4‑6:    Global – Forecast for CD30 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4‑7:    Global – Forecast for CD33 Antigen CAR-T Cell Therapy Market (Million US$), 2017 – 2028
Figure 4‑8:    Global – Forecast for HER2 Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4‑9:    Global – Forecast for MESO Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4‑10:    Global – Forecast for EGFRvIII Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 4‑11:    Global – Forecast for Others Antigen CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5‑1:    North America – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5‑2:    North America – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5‑3:    Europe – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5‑4:    Europe – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5‑5:    Asia Pacific – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5‑6:    Asia Pacific – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5‑7:    Latin America – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5‑8:    Latin America – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5‑9:    Middle East – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5‑10:    Middle East – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 5‑11:    Africa – CAR-T Cell Therapy Market (Million US$), 2017 – 2019
Figure 5‑12:    Africa – Forecast for CAR-T Cell Therapy Market (Million US$), 2020 – 2028
Figure 7‑1:    China – By Cities CAR-T Cells Clinical Trials (Number), 2017
Figure 11‑1:    Global – CAR-T New & Total Clinical Trials (Number), 2012-2017
Figure 11‑2:    Global – By Phase CAR-T Clinical Trials (Number), 2017
Figure 13‑1:    Novartis – Global Sales (Million US$), 2015 - 2019
Figure 13‑2:    Novartis – Forecast for Global Sales (Million US$), 2020 - 2028
Figure 14‑1:    Gilead Sciences – Global Sales (Million US$), 2017 - 2019
Figure 14‑2:    Gilead Sciences – Forecast for Global Sales (Million US$), 2020 - 2028
Figure 15‑1:    Celgene – Global Sales (Million US$), 2013 - 2019
Figure 15‑2:    Celgene – Forecast for Global Sales (Million US$), 2020 - 2028
Figure 16‑1:    Celyad – Global Sales (Million US$), 2013 - 2019
Figure 16‑2:    Celyad – Forecast for Global Sales (Million US$), 2020 - 2028

List of Tables:

Table 3 1: Global – CAR-T Cell Therapy Targeted Antigens Market Share (Percent), 2017 – 2019
Table 3 2: Global – CAR-T Cell Therapy Targeted Antigens Market Share (Percent), 2020 – 2028
Table 6 1: Global – Details of CD19 CAR-T Studies, 2018
Table 6 2: Global – Details of CD20 CAR-T Studies, 2018
Table 6 3: Global – Details of CD22 CAR-T Studies, 2018
Table 6 4: Global – Details of CD30 CAR-T Studies, 2018
Table 6 5: Global – Details of CD33 CAR-T Studies, 2018
Table 6 6: Global – Details of EGFRvIII CAR-T Studies, 2018
Table 6 7: Global – Details of GD2 CAR-T Studies, 2018
Table 6 8: Global – Details of HER1 CAR-T Studies, 2018
Table 6 9: Global – Details of HER2 CAR-T Studies, 2018
Table 6 10: Global – Details of MESO CAR-T Studies, 2018
Table 7 1: China - CD19 Directed CAR-T Cells Clinical Trials, 2017
Table 7 2: China – Non-CD19 Directed CAR-T Cells Clinical Trials, 2017
Table 7 3: China – Solid Tumors CAR-T Cells Clinical Trials, 2017
Table 10 1: Global – Venture Capital Investments (Million US$) in CAR-T Cell Therapy, 2011 – 2017
Table 10 2: Global – Initial Public Offerings (Million US$) in CAR-T Cell Therapy, 2011 – 2016
Table 10 3: Global - CAR-T Companies Strategic Partnerships/Acquisitions, 2012-2017
Table 10 4: Global – Key CAR-T Technology Deals, 2012-2017